Nedosiran us patent?

Nedosiran itself isn’t a single US patent with that drug name. Nedosiran (DCR-PHXC) is an siRNA therapy in development for primary hyperoxaluria type 1, and its US protection is through multiple patent families owned by the developers (historically Dicerna Pharmaceuticals, now part of Novo Nordisk). The US patents cover things like:

- LDHA-targeting siRNA sequences (composition of matter) for reducing oxalate production in PH1.
- Uses of LDHA silencing to treat hyperoxaluria.
- GalNAc-siRNA delivery to the liver (delivery framework likely relevant to Nedosiran’s delivery method).

In short: there isn’t a single “Nedosiran US patent”—there are multiple US patents and applications covering the underlying siRNA sequences, their use for PH1, and the delivery method.

How to find the exact US patent numbers and status
- Public patent databases to search:
- Google Patents (patents.google.com)
- USPTO Patents Full-Text and Image Database (PatFT)
- Espacenet (worldwide patent database)
- Useful search terms:
- “LDHA siRNA” AND “primary hyperoxaluria” US patent
- “lactate dehydrogenase A siRNA” US patent
- “hyperoxaluria” AND “siRNA” US patent
- “Dicerna” AND “LDHA” US patent
- “DCR-PHXC” US patent
- “GalNAc-siRNA” AND “LDHA” US patent (delivery targeting liver)
- Check assignees:
- Dicerna Pharmaceuticals (and its successors/affiliate Novo Nordisk)
- Any related family members under Novo Nordisk as the patent holder

Notes
- Patent families often include multiple related US applications and continuation patents; there can be early priority dates spanning several years.
- In addition to composition-of-matter patents, there are method-of-use and delivery patents that may cover Nedosiran’s approach.
- For any legal or business decision (e.g., freedom-to-operate, licensing), consult a patent attorney who can review the specific claims and status.

If you’d like, tell me and I’ll help look up the current US patent numbers and summarize their status (granted vs. pending, expiration dates, key claim scope).